JP2023511774A5 - - Google Patents

Info

Publication number
JP2023511774A5
JP2023511774A5 JP2022546621A JP2022546621A JP2023511774A5 JP 2023511774 A5 JP2023511774 A5 JP 2023511774A5 JP 2022546621 A JP2022546621 A JP 2022546621A JP 2022546621 A JP2022546621 A JP 2022546621A JP 2023511774 A5 JP2023511774 A5 JP 2023511774A5
Authority
JP
Japan
Prior art keywords
cdr
seq
represented
antibody
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022546621A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023511774A (ja
JP7807379B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/012666 external-priority patent/WO2021154476A1/en
Publication of JP2023511774A publication Critical patent/JP2023511774A/ja
Publication of JP2023511774A5 publication Critical patent/JP2023511774A5/ja
Priority to JP2026004811A priority Critical patent/JP2026086434A/ja
Application granted granted Critical
Publication of JP7807379B2 publication Critical patent/JP7807379B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022546621A 2020-01-31 2021-01-08 抗トランスフェリン受容体(tfr)抗体およびその使用 Active JP7807379B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026004811A JP2026086434A (ja) 2020-01-31 2026-01-15 抗トランスフェリン受容体(tfr)抗体およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062968252P 2020-01-31 2020-01-31
US62/968,252 2020-01-31
US202063055405P 2020-07-23 2020-07-23
US63/055,405 2020-07-23
PCT/US2021/012666 WO2021154476A1 (en) 2020-01-31 2021-01-08 Anti-transferrin receptor (tfr) antibody and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026004811A Division JP2026086434A (ja) 2020-01-31 2026-01-15 抗トランスフェリン受容体(tfr)抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2023511774A JP2023511774A (ja) 2023-03-22
JP2023511774A5 true JP2023511774A5 (cg-RX-API-DMAC7.html) 2024-01-18
JP7807379B2 JP7807379B2 (ja) 2026-01-27

Family

ID=77079923

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022546621A Active JP7807379B2 (ja) 2020-01-31 2021-01-08 抗トランスフェリン受容体(tfr)抗体およびその使用
JP2026004811A Pending JP2026086434A (ja) 2020-01-31 2026-01-15 抗トランスフェリン受容体(tfr)抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026004811A Pending JP2026086434A (ja) 2020-01-31 2026-01-15 抗トランスフェリン受容体(tfr)抗体およびその使用

Country Status (11)

Country Link
US (1) US20230113823A1 (cg-RX-API-DMAC7.html)
EP (1) EP4096695A4 (cg-RX-API-DMAC7.html)
JP (2) JP7807379B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220134584A (cg-RX-API-DMAC7.html)
CN (1) CN115427059A (cg-RX-API-DMAC7.html)
AU (1) AU2021213042A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022014771A2 (cg-RX-API-DMAC7.html)
CA (1) CA3163290A1 (cg-RX-API-DMAC7.html)
IL (1) IL295022A (cg-RX-API-DMAC7.html)
MX (1) MX2022009418A (cg-RX-API-DMAC7.html)
WO (1) WO2021154476A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
EP4087653A4 (en) * 2020-01-10 2024-06-19 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20230111212A1 (en) * 2020-01-10 2023-04-13 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2021154477A1 (en) 2020-01-31 2021-08-05 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
WO2023283623A1 (en) 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
US11939391B2 (en) * 2021-12-06 2024-03-26 MedAbome, Inc. Anti-TfR1 antibody MAb11-22.1 conjugates for cancer treatment
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
IL318627A (en) * 2022-07-29 2025-03-01 Regeneron Pharma Anti-TFR charge fusions and methods of using them
WO2024168801A1 (zh) * 2023-02-17 2024-08-22 南京融捷康生物科技有限公司 抗TfR1的单域抗体及其用途
KR20260044219A (ko) 2023-07-21 2026-04-01 매로우 테라퓨틱스, 인크. 조혈 세포 표적화 접합체 및 관련 방법
WO2025265092A1 (en) * 2024-06-21 2025-12-26 Dyne Therapeutics, Inc. Complexes and uses thereof for treating pompe disease
CN120209138B (zh) * 2025-05-29 2025-10-03 杭州广科安德生物科技有限公司 Tff3、osm蛋白的抗体及其组合和在结直肠癌诊断中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
CA2922544A1 (en) * 2013-08-28 2015-03-05 Stemcentrx, Inc. Engineered anti-dll3 conjugates and methods of use
JP6779876B2 (ja) * 2014-11-19 2020-11-04 ジェネンテック, インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
IL257065B (en) * 2015-07-22 2022-07-01 Inatherys Antibodies to tfr for use in the treatment of proliferative and inflammatory diseases
AU2016335750B2 (en) * 2015-10-07 2023-05-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
KR20250007678A (ko) * 2016-05-13 2025-01-14 더 제너럴 하스피탈 코포레이션 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체
DK3473270T5 (da) * 2016-06-20 2024-09-09 Genahead Bio Inc Konjugat af antistof-lægemiddel
TWI833178B (zh) * 2016-12-26 2024-02-21 日商Jcr製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
BR112019017628A2 (pt) * 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
CN118638787A (zh) * 2017-12-06 2024-09-13 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
CN111683972A (zh) * 2018-02-05 2020-09-18 Jcr制药股份有限公司 用于将药剂递送至肌肉的方法
UY38247A (es) * 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación

Similar Documents

Publication Publication Date Title
CN112646031B (zh) 抗4-1bb纳米抗体及其用途
US9758586B2 (en) Chimeric rabbit/human ROR1 antibodies
JP7663977B2 (ja) 抗pd―l1抗体およびその用途
WO2020168555A1 (zh) Cd3抗原结合片段及其应用
AU2010238723A1 (en) Anti-human ROR1 antibodies
KR20140034877A (ko) 항슈도모나스 psl 결합 분자 및 그의 용도
CN110856446A (zh) 抗pd-l1抗体及其用途
KR20130130825A (ko) 골관절염 및 통증의 치료 방법
TW201026325A (en) Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment
TWI845724B (zh) 用於偶聯的多肽複合物及其應用
WO2021155635A1 (zh) 抗cd3和cd123双特异性抗体及其用途
KR20230125042A (ko) 항-tslp 나노항체 및 이의 응용
JP7755062B2 (ja) 新規抗l1cam抗体
TW202506189A (zh) 配體-細胞毒性藥物綴合物及其醫藥用途
CN120712286A (zh) 抗体、抗原结合片段和使用方法
US20240075158A1 (en) Complex of anti-il-4r antibody or antigen-binding fragment thereof and medical use thereof
JP2025506248A5 (cg-RX-API-DMAC7.html)
TW202535883A (zh) 配體–細胞毒性藥物偶聯物及其藥物用途
JP2025524306A (ja) Itga2を標的とする抗体及びそれを含む抗体薬物複合体
IL324637A (en) Antibody specifically binding to cll1, and preparation method therefor and use thereof
CN120424212A (zh) 抗FGFR2b抗体及抗体药物偶联物
TW202432185A (zh) 配體-細胞毒性藥物綴合物及其藥物用途
CN120187752A (zh) 人源化的l1cam抗体药物偶联物
TWI843182B (zh) 一種抗b7-h4抗體及其製備方法和應用
TW202434637A (zh) 抗體、抗原結合片段及其醫藥用途